Avexitide Cut Dangerous Low-Blood-Sugar Events by 55%. Full Phase 3 Data Are Still Missing.
A 78-person Phase 3 trial found 55% fewer Level 2 and Level 3 hypoglycemic events with avexitide. The signal is strong, but the complete dataset is not public.
A drug built to block GLP-1, rather than copy it, has cleared a pivotal test. In the Phase 3 LUCIDITY trial, avexitide reduced the combined rate of clinically important and severe low-blood-sugar events by 55% versus placebo in adults with post-bariatric hypoglycemia. The result could put the first approved treatment for this overlooked complication of weight-loss surgery within reach.
That headline is strong, but it is not the whole dataset. Amylyx released top-line results from 78 participants, not a peer-reviewed paper. The company disclosed the primary relative reduction and a very small p-value, but not the event rates in each arm, confidence intervals, participant-level response rates, or full adverse-event tables. This is a credible Phase 3 signal with an important transparency gap.
The news: a pivotal trial met its main endpoint
LUCIDITY enrolled 78 adults who had post-bariatric hypoglycemia after Roux-en-Y gastric bypass. At 21 U.S. sites, participants were randomized in a 3:2 ratio to receive either 90 mg of avexitide by subcutaneous injection once daily or placebo. The double-blind comparison lasted 16 weeks, followed by a planned 32-week open-label extension.
The primary endpoint combined two event types. Level 2 hypoglycemia meant a glucose value below 54 mg/dL measured by self-monitoring. Level 3 referred to severe episodes involving altered mental or physical function that required help from another person. According to the sponsor, avexitide reduced the rate of this composite by 55% relative to placebo, with p=0.000003.
The company also reported that all secondary endpoints were met. Those included Level 2 events captured by finger-stick testing, Level 2 events captured by continuous glucose monitoring, and independently adjudicated Level 3 events. Exact results for those secondary outcomes were not included in the top-line announcement.
Safety looked manageable over 16 weeks. Most adverse events were described as mild or moderate, and no serious adverse event was attributed to avexitide. Diarrhea, injection-site redness, and injection-site bruising were the most common reported problems. Neither treatment group had a change in body weight during the controlled period.
Why low blood sugar can appear after bariatric surgery
Post-bariatric hypoglycemia, often shortened to PBH, usually appears after meals and can emerge long after the surgical follow-up period has ended. Roux-en-Y surgery changes how quickly nutrients reach the intestine. In susceptible people, a meal can trigger an exaggerated GLP-1 response, followed by too much insulin and a rapid fall in glucose one to three hours later.
This is not simply hunger, ordinary fatigue, or a mildly uncomfortable glucose dip. Neuroglycopenia means the brain is not receiving enough glucose. A severe episode can cause confusion, poor coordination, loss of consciousness, or a seizure. Recurrent events can interfere with work, driving, exercise, and independent living.
Estimates vary because studies use different definitions and detection methods. The new Phase 2b paper notes that biochemical or symptomatic PBH may complicate up to 30% of Roux-en-Y procedures and up to 10% of sleeve gastrectomies, while the sponsor estimates clinically recognized symptomatic disease in roughly 8% of U.S. patients who underwent the two common procedures. These figures should not be treated as interchangeable.
Avexitide flips the usual GLP-1 story
Most people now associate GLP-1 with semaglutide, tirzepatide, and weight loss. Those medicines activate incretin pathways. Avexitide, also called exendin 9-39, does the opposite at the GLP-1 receptor. It is a 31-amino-acid peptide antagonist designed to compete with GLP-1 and reduce the excessive insulin release that drives PBH.
That distinction matters. Avexitide is not being developed as another obesity drug, and the LUCIDITY result does not suggest that people using GLP-1 agonists should block those drugs. It is a targeted treatment for a specific postsurgical disorder in which the normal meal-response pathway appears to overshoot.
The mechanism also explains why stable body weight in LUCIDITY is useful information. The goal was fewer dangerous glucose crashes, not additional weight loss. A therapy that treated PBH by causing further weight change would introduce a different clinical trade-off.
The Phase 3 result did not come out of nowhere
Earlier controlled work gave the program a reasonable foundation. In the randomized, placebo-controlled PREVENT crossover trial, 18 people with PBH after Roux-en-Y surgery received avexitide for 28 days. Both tested dosing regimens improved the lowest post-meal glucose level and reduced several measures of hypoglycemia without a relevant increase in hyperglycemia.
A separate Phase 2b crossover study, newly published in 2026, broadened the surgical population. Sixteen participants with hypoglycemia after Roux-en-Y, sleeve gastrectomy, total gastrectomy, or Nissen fundoplication completed two 14-day avexitide regimens in random order. Compared with baseline, 90 mg once daily reduced daytime Level 2 events measured by continuous glucose monitoring by 59.0%, Level 3 events by 66.1%, and time below 54 mg/dL by 64%. No serious adverse events or treatment-related discontinuations were reported.
Those numbers are encouraging, but the Phase 2b design was open-label and used each participant's run-in period as the comparison. LUCIDITY is more persuasive because it was randomized, double-blind, placebo-controlled, multicenter, and longer. The alignment between earlier and later studies strengthens the signal even though full Phase 3 data remain unavailable.
What the result does not yet prove
First, 55% is a relative rate reduction. Without the absolute event rates, readers cannot tell how many episodes were prevented per patient or how the benefit varied between frequent and less-frequent events. A large relative change can have very different practical meaning depending on the starting rate.
Second, the controlled trial lasted 16 weeks. PBH is chronic, so durability, adherence, injection burden, and uncommon adverse effects need longer follow-up. The open-label extension may answer some of those questions, but it cannot preserve the same blinded placebo comparison.
Third, LUCIDITY enrolled people after Roux-en-Y gastric bypass. The Phase 2b study included a few other upper-gastrointestinal procedures, but this pivotal result should not automatically be generalized to sleeve gastrectomy, total gastrectomy, or Nissen fundoplication.
Fourth, the only public Phase 3 results currently come from Amylyx. The company sponsored the trial and plans to file a New Drug Application. That does not invalidate the result, but independent review of the protocol, statistical analysis, full safety data, and subgroup findings remains essential.
What treatment looks like before approval
Current care starts with diagnosis and structured dietary management, not an investigational injection. Society for Endocrinology guidance recommends confirming Whipple's triad where possible, excluding other causes of hypoglycemia, and using small, frequent meals with controlled carbohydrate portions. Acarbose is the recommended first pharmacologic option in that guideline, followed by short-acting pasireotide or octreotide when needed. Rescue glucagon education may be appropriate for people with frequent severe episodes.
The same guidance described avexitide as promising but investigational. That remains true today. Amylyx has said an expanded-access program is open to eligible U.S. adults, and it plans to submit an NDA by the end of 2026. Breakthrough Therapy and Orphan Drug designations can support development and review, but neither is marketing approval.
Anyone with confusion, fainting, seizure, or a glucose reading below 54 mg/dL needs prompt medical assessment. People who suspect PBH should not try to reproduce the effect of a GLP-1 antagonist with unregulated peptides or change diabetes medicines on their own.
The Oria take
LUCIDITY is one of the clearer examples of peptide medicine solving a narrow physiological problem rather than chasing a broad wellness claim. The drug has a defined target, a plausible mechanism, consistent earlier trials, and now a positive randomized Phase 3 result.
The careful conclusion is not that avexitide is proven and ready. It is that the program crossed the most important efficacy threshold disclosed so far. Approval will depend on the complete package, and clinical confidence should rise only after the full dataset is presented or published. For people living with recurrent PBH, however, a 55% placebo-adjusted reduction in dangerous events is a result worth watching.
Sources
Evidence grade: B−. A randomized, double-blind, placebo-controlled Phase 3 trial met its prespecified primary endpoint with supportive earlier studies. The grade is capped because the Phase 3 evidence is still a sponsor-reported top-line release without absolute event rates, confidence intervals, complete secondary outcomes, full safety tables, or peer-reviewed publication.
Medical disclaimer: This article is for education and research only. It is not medical advice, diagnosis, or a treatment recommendation. Avexitide is investigational and is not FDA-approved for post-bariatric hypoglycemia. Oria exists to help readers separate emerging evidence from marketing claims; decisions about suspected hypoglycemia, glucose monitoring, diet, medication, or clinical-trial access belong with a qualified clinician.
Build Your Personalised Protocol
Turn your research into a personalised supplementation protocol with the BioStack Generator.